ArticleAnnals of surgical oncology2025

Real-World Single-Center Experience with Neoadjuvant Gemcitabine, Cisplatin, and Durvalumab in Borderline Resectable Cholangiocarcinoma.

Yawen Dong et al.PubMed ↗Publisher ↗

No numbers read from the abstract.